Congress Materials

Medical Information
Gulf Countries
 

This medical information website is intended only for healthcare professionals in the following Gulf Countries (UAE, Oman, Bahrain, Qatar and Kuwait). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
SelectI am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
I am a patient / caregiverNo, go back to the patient portal
SelectI am a patient / caregiverNo, go back to the patient portal
I am a Healthcare Professional in another country.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Lesokhin AM, Arnulf B, Niesvizky R, Mohty M, Bahlis NJ, Tomasson MH, Rodrίguez-Otero P, Quach H, Raje NS, Iida S, Raab M-S, Czibere A, Sullivan S, Leip E, Viqueira A, Leleu X June 10, 2022 EHA 2022 Hematology

A Phase 2 Trial of Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma: Initial Safety Results for MagnetisMM-3

View Presentation View Abstract Plain Language Summary
Poster
Montesinos P, Kota V, Brandwein J, Bousset P, Benner RJ, Vandendries E, McMullin MF June 10, 2022 EHA 2022 Hematology

A Phase 4 Study of Fractionated Gemtuzumab Ozogamicin on QT Interval and Safety in Patients With Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

View Presentation View Abstract Plain Language Summary
Poster
Cortes JE, Milojkovic D, Gambacorti-Passerini C, Garcia-Gutierrez V, Mauro MJ, Leip E, Purcell S, Viqueira A, Brummendorf TH June 10, 2022 EHA 2022 Hematology

Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia: Gastrointestinal, Liver, Effusion and Renal Safety Characterization in the BFORE Trial

View Presentation View Abstract Plain Language Summary
Poster
Russell-Smith A, Shah R, Silverstein AR, Petrilla A, Leinwand B, Norris D, Schroeder A June 10, 2022 EHA 2022 Hematology

Characteristics, Healthcare Utilization, and Costs Associated With Inotuzumab Ozogamicin, Blinatumomab, or Other Agents for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

View Presentation
Poster
Gambacorti-Passerini C, Brummendorf TH, Ernst T, Leip E, Purcell S, Viqueira A, Giles FJ, Rosti G, Hochhaus A June 10, 2022 EHA 2022 Hematology

Efficacy and Safety of Bosutinib in Later-Line Patients With Chronic Myeloid Leukemia: A Sub-Analysis From the Phase 4 BYOND Trial

View Presentation View Abstract Plain Language Summary
Poster
Dalovisio A, Bahlis NJ, Raje NS, Costello CL, Dholaria B, Solh M, Levy MY, Tomasson MH, Dube H, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Chu MP, Gasparetto C, Sebag M, Lesokhin AM June 10, 2022 EHA 2022 Hematology

Updated Results From the Ongoing Phase 1 Study of Elranatamab, a BCMA Targeted T-Cell Redirecting Immunotherapy, for Patients With Relapsed or Refractory Multiple Myeloma

View Presentation View Abstract Plain Language Summary